Retatrutide vs Sermorelin
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and Sermorelin (GHRH 1-29). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | Sermorelin GHRH 1-29, GRF 1-29 |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | Withdrawn (off-label use continues) |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Obesity and weight management | Growth hormone deficiency and anti-aging |
| Weight Loss % | 28.7% | N/A |
| Monthly Cost | $1,200 - $1,500/mo | $150 - $350/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 200-500mcg daily before bed |
| Frequency | Weekly | Daily |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Moderate |
| Clinical Trial Phase | Phase 3 | N/A |
Key Differences
- 1Retatrutide has clinical weight loss data (28.7%), while Sermorelin is not primarily indicated for weight loss.
- 2Sermorelin is generally more affordable ($150 - $350/mo) compared to Retatrutide ($1,200 - $1,500/mo).
- 3Retatrutide is dosed weekly, while Sermorelin is daily.
- 4Retatrutide has high-quality evidence, while Sermorelin has moderate-quality evidence.
- 5They belong to different categories: Retatrutide (Weight Loss) vs Sermorelin (Growth Hormone).
Which Is Better For...
Sermorelin
More budget-friendly option with lower monthly costs
Retatrutide
More convenient dosing schedule (weekly)
Sermorelin
Fewer commonly reported side effects
Retatrutide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| Sermorelin | $150 - $350/mo | Withdrawn (off-label use continues) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. Sermorelin works via Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH. They differ in FDA approval status, efficacy data, and cost.
Retatrutide has demonstrated 28.7% average weight loss in clinical trials. Sermorelin is not primarily used for weight loss.
Retatrutide typically costs $1,200 - $1,500/mo, while Sermorelin costs $150 - $350/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). Sermorelin is not FDA-approved (Withdrawn (off-label use continues)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of Sermorelin include Injection site reactions, Flushing, Headache. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideSermorelin is a bioidentical synthetic version of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of the full 44-amino acid GHRH molecule. It was previously FDA-approved...
View Full Sermorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and Sermorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.